Radius Health - RDUS Stock Forecast, Price & News

Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts.

Radius Health Price Performance

Radius Health stock opened at $10.10 on Friday. Radius Health has a one year low of $4.97 and a one year high of $23.00. The company's fifty day moving average price is $9.49 and its two-hundred day moving average price is $8.17.

Analyst Ratings Changes

Several equities analysts recently weighed in on RDUS shares. StockNews.com lowered shares of Radius Health from a "buy" rating to a "hold" rating in a report on Tuesday. The Goldman Sachs Group decreased their price target on Radius Health from $9.00 to $8.00 and set a "neutral" rating for the company in a research note on Tuesday, May 24th. SVB Leerink raised their price target on shares of Radius Health from $7.00 to $10.00 and gave the stock a "market perform" rating in a research report on Friday, June 24th. Finally, Bank of America raised Radius Health from an "underperform" rating to a "neutral" rating and set a $8.00 target price on the stock in a research report on Wednesday, June 8th. One research analyst has rated the stock with a sell rating and five have assigned a hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $8.60.

Insider Buying and Selling at Radius Health

In other news, major shareholder Target N. V. Biotech acquired 477,824 shares of the firm's stock in a transaction that occurred on Wednesday, May 18th. The stock was acquired at an average cost of $5.57 per share, with a total value of $2,661,479.68. Following the acquisition, the insider now owns 8,733,538 shares in the company, valued at $48,645,806.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Radius Health news, major shareholder Target N. V. Biotech purchased 477,824 shares of the company's stock in a transaction on Wednesday, May 18th. The shares were bought at an average cost of $5.57 per share, with a total value of $2,661,479.68. Following the transaction, the insider now directly owns 8,733,538 shares in the company, valued at approximately $48,645,806.66. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Rubric Capital Management Lp acquired 4,012 shares of Radius Health stock in a transaction dated Wednesday, August 10th. The stock was acquired at an average cost of $10.07 per share, with a total value of $40,400.84. Following the completion of the transaction, the insider now directly owns 6,963,317 shares of the company's stock, valued at approximately $70,120,602.19. The disclosure for this purchase can be found here. Corporate insiders own 1.73% of the company's stock.